Our mission is to advance companies developing treatments for neurodegenerative disease and ALS in particular. Our commitment to this mission is fueled by personal ties to ALS. Never losing sight of this mission, we have joined our complementary skills and years of experience together in order to successfully bring novel drugs and technologies to the market and make a return for our investors (social impact as well as financial return). [Read more]. Our scientific advisory board is comprised of internationally renowned key opinion leaders.
The ALS Investment Fund is managed by SUNU Ventures BV, a Dutch limited company.